Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2006 2
2007 1
2008 3
2009 2
2010 1
2012 1
2013 5
2014 4
2015 1
2016 3
2017 2
2018 4
2019 5
2020 2
2021 3
2022 7
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
NUP214-ABL1 fusion in childhood T-ALL.
Veltri G, Sandei M, Silvestri D, Bresolin S, Pession A, Santoro N, Ziino O, Veltroni M, Rizzari C, Biffi A, Valsecchi MG, Conter V, Buldini B, Accordi B, Serafin V. Veltri G, et al. Among authors: silvestri d. Pediatr Blood Cancer. 2022 Sep;69(9):e29643. doi: 10.1002/pbc.29643. Epub 2022 Mar 6. Pediatr Blood Cancer. 2022. PMID: 35253360 No abstract available.
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia.
Palmi C, Bresolin S, Junk S, Fazio G, Silvestri D, Zaliova M, Oikonomou A, Scharov K, Stanulla M, Moericke A, Zimmermann M, Schrappe M, Buldini B, Bhatia S, Borkhardt A, Saitta C, Galbiati M, Bardini M, Lo Nigro L, Conter V, Valsecchi MG, Biondi A, Te Kronnie G, Cario G, Cazzaniga G. Palmi C, et al. Among authors: silvestri d. Hemasphere. 2023 May 26;7(6):e892. doi: 10.1097/HS9.0000000000000892. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37304931 Free PMC article.
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.
Caserta C, Nucera S, Barcella M, Fazio G, Naldini MM, Pagani R, Pavesi F, Desantis G, Zonari E, D'Angiò M, Capasso P, Lombardo A, Merelli I, Spinelli O, Rambaldi A, Ciceri F, Silvestri D, Valsecchi MG, Biondi A, Cazzaniga G, Gentner B. Caserta C, et al. Among authors: silvestri d. Leukemia. 2023 Oct;37(10):1994-2005. doi: 10.1038/s41375-023-02009-5. Epub 2023 Aug 28. Leukemia. 2023. PMID: 37640845
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
Oikonomou A, Valsecchi L, Quadri M, Watrin T, Scharov K, Procopio S, Tu JW, Vogt M, Savino AM, Silvestri D, Valsecchi MG, Biondi A, Borkhardt A, Bhatia S, Cazzaniga G, Fazio G, Bardini M, Palmi C. Oikonomou A, et al. Among authors: silvestri d. Biochem Pharmacol. 2023 Nov;217:115809. doi: 10.1016/j.bcp.2023.115809. Epub 2023 Sep 17. Biochem Pharmacol. 2023. PMID: 37717691 Free article.
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120.
Fazio G, Bresolin S, Silvestri D, Quadri M, Saitta C, Vendramini E, Buldini B, Palmi C, Bardini M, Grioni A, Rigamonti S, Galbiati M, Mecca S, Savino AM, Peloso A, Tu JW, Bhatia S, Borkhardt A, Micalizzi C, Lo Nigro L, Locatelli F, Conter V, Rizzari C, Valsecchi MG, Te Kronnie G, Biondi A, Cazzaniga G. Fazio G, et al. Among authors: silvestri d. EBioMedicine. 2022 Sep;83:104224. doi: 10.1016/j.ebiom.2022.104224. Epub 2022 Aug 16. EBioMedicine. 2022. PMID: 35985167 Free PMC article.
Impact of Mercaptopurine Metabolites on Disease Outcome in the AIEOP-BFM ALL 2009 Protocol for Acute Lymphoblastic Leukemia.
Franca R, Stocco G, Kiren V, Tessitore A, Fagioli F, Quarello P, Bertorello N, Rizzari C, Colombini A, Bettini LR, Locatelli F, Vinti L, Girardi K, Silvestri D, Valsecchi MG, Decorti G, Rabusin M. Franca R, et al. Among authors: silvestri d. Clin Pharmacol Ther. 2023 Nov;114(5):1082-1092. doi: 10.1002/cpt.3022. Epub 2023 Aug 24. Clin Pharmacol Ther. 2023. PMID: 37550838
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol.
Rizzari C, Möricke A, Valsecchi MG, Conter V, Zimmermann M, Silvestri D, Attarbaschi A, Niggli F, Barbaric D, Stary J, Elitzur S, Cario G, Vinti L, Boos J, Zucchetti M, Lanvers-Kaminsky C, von Stackelberg A, Biondi A, Schrappe M. Rizzari C, et al. Among authors: silvestri d. Hemasphere. 2023 Jun 1;7(6):e893. doi: 10.1097/HS9.0000000000000893. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37275740 Free PMC article.
Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia.
Heilmann J, Vieth S, Möricke A, Attarbaschi A, Barbaric D, Bodmer N, Colombini A, Dalla-Pozza L, Elitzur S, Izraeli S, Mann G, Niggli F, Silvestri D, Stary J, Rizzari C, Valsecchi MG, Zapotocka E, Zimmermann M, Cario G, Schrappe M, Conter V. Heilmann J, et al. Among authors: silvestri d. Haematologica. 2023 Dec 1;108(12):3278-3286. doi: 10.3324/haematol.2022.281788. Haematologica. 2023. PMID: 37021527 Free PMC article.
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
Conter V, Valsecchi MG, Cario G, Zimmermann M, Attarbaschi A, Stary J, Niggli F, Dalla Pozza L, Elitzur S, Silvestri D, Locatelli F, Möricke A, Engstler G, Smisek P, Bodmer N, Barbaric D, Izraeli S, Rizzari C, Boos J, Buldini B, Zucchetti M, von Stackelberg A, Matteo C, Lehrnbecher T, Lanvers-Kaminsky C, Cazzaniga G, Gruhn B, Biondi A, Schrappe M. Conter V, et al. Among authors: silvestri d. J Clin Oncol. 2024 Mar 10;42(8):915-926. doi: 10.1200/JCO.23.01388. Epub 2023 Dec 14. J Clin Oncol. 2024. PMID: 38096462
52 results